BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34882515)

  • 1. Aseptic meningitis after SARS-CoV-2 Pfizer/BioNTech vaccination.
    Dupon V; Arnaert S; Van Haute E; Vulsteke F; Diet G; De Schoenmakere G
    Acta Clin Belg; 2022 Dec; 77(6):976-979. PubMed ID: 34882515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A child with crescentic glomerulonephritis following SARS-CoV-2 mRNA (Pfizer-BioNTech) vaccination.
    Kim S; Jung J; Cho H; Lee J; Go H; Lee JH
    Pediatr Nephrol; 2023 Jan; 38(1):299-302. PubMed ID: 35854121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination.
    Algaissi A; Alamer E; Jeraiby M; Alomaish A; Elrhima O; Qumayi S; Qasir NA; Areeshi H; Masmali A; Alhazmi A
    Saudi Med J; 2022 Jun; 43(6):567-571. PubMed ID: 35675927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021.
    Lutrick K; Rivers P; Yoo YM; Grant L; Hollister J; Jovel K; Khan S; Lowe A; Baccam Z; Hanson H; Olsho LEW; Fowlkes A; Caban-Martinez AJ; Porter C; Yoon S; Meece J; Gaglani M; Burns J; Mayo Lamberte J; Nakayima Miiro F; Bissonnette A; LeClair L; Kutty PK; Romine JK; Stefanski E; Edwards LJ; Ellingson K; Gerald JK; Bedrick EJ; Madhivanan P; Krupp K; Gerald LB; Thompson M; Burgess JL
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1761-1765. PubMed ID: 34968373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
    Casas Fischer R
    Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aseptic Meningitis after BNT-162b2 COVID-19 Vaccination: Case Report and Literature Review.
    Kato Y; Osada T; Araki N; Takahashi S
    Keio J Med; 2023 Dec; 72(4):102-105. PubMed ID: 37743529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extensive Cerebral Venous Sinus Thrombosis (CVST) After the First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine without Thrombotic Thrombocytopenia Syndrome (TTS) in a Healthy Woman.
    Alhashim A; Hadhiah K; Al Khalifah Z; Alhaddad FM; Al ARhain SA; Bin Saif FH; Abid A; Al Gamdi O; Alsulaiman F; AlQarni M
    Am J Case Rep; 2022 Feb; 23():e934744. PubMed ID: 35136010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient plasma viral rebound after SARS-CoV-2 vaccination in an exceptional HIV-1 elite controller woman.
    Di Girolamo L; Ferrara M; Trevisan G; Longo BM; Allice T; Burdino E; Alladio F; Fantino S; Di Perri G; Calcagno A; Bonora S
    Virol J; 2023 Jun; 20(1):123. PubMed ID: 37312093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of Angioimmunoblastic T Cell Lymphoma After Receiving First Dose of Pfizer/BioNTech (BNT162b2) Vaccine: A Case Report.
    Khatri JK; Tahboub I; Anwar K; Masoudi M; Graffeo V; Jamil MO
    J Investig Med High Impact Case Rep; 2024; 12():23247096241231645. PubMed ID: 38761096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Age, Gender and Comorbidities Upon SARS-CoV-2 Spike Antibody Induction After Two Doses of Sinopharm Vaccine and the Effect of a Pfizer/BioNtech Booster Vaccine.
    Farid E; Herrera-Uribe J; Stevenson NJ
    Front Immunol; 2022; 13():817597. PubMed ID: 35711448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroid-responsive aseptic meningitis after BNT162b2 SARS-CoV-2 vaccine.
    Reis Carneiro D; Matos A; Morgadinho A
    Rev Neurol (Paris); 2022; 178(1-2):160-161. PubMed ID: 34799078
    [No Abstract]   [Full Text] [Related]  

  • 15. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
    Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Status migrainosus: a potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine-a case report.
    Consoli S; Dono F; Evangelista G; D'Apolito M; Travaglini D; Onofrj M; Bonanni L
    Neurol Sci; 2022 Feb; 43(2):767-770. PubMed ID: 34807361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination.
    Aydoğan Bİ; Ünlütürk U; Cesur M
    Endocrine; 2022 Oct; 78(1):42-46. PubMed ID: 35809159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De Novo Minimal Change Disease following Vaccination with the Pfizer/BioNTech SARS-CoV-2 Vaccine in a Living Kidney Donor.
    Marinaki S; Kolovou K; Liapis G; Skalioti C; Tsiakas S; Boletis I
    Medicina (Kaunas); 2021 Dec; 58(1):. PubMed ID: 35056345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated CD21
    Bergman P; Wullimann D; Gao Y; Wahren Borgström E; Norlin AC; Lind Enoksson S; Aleman S; Ljunggren HG; Buggert M; Smith CIE
    J Clin Immunol; 2022 May; 42(4):716-727. PubMed ID: 35290571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.